Statins for the primary prevention of cardiovascular disease
31 results
1 - 31
USPSTF 2022: updated review of statins for the primary prevention of cardiovascular disease- Statins ineffective for primary prevention in patients 75 years or older without diabetes
- USPSTF 2016 recommendations on statin use for primary prevention of CVD
- Statins best for cardiovascular and all-cause mortality prevention overall and for primary prevention (PEER umbrella review)
- Smaller benefit of statins without heart disease
- Statins for hyperlipidemia reduce all-cause mortality
- Statins of modest benefit for low- to moderate-risk persons (NNT ~ 80)
- More nuanced guidelines for lipid lowering to prevent CV disease
- Statins effective for LDL 190 mg/dL or higher, regardless of risk level
- Lipid treatment for primary prevention not effective in older adults
- AHA/ACC guideline for the primary prevention of stroke
- Statin therapy decreases cardiac events
- Peri-op fluvastatin reduces myocardial ischemia after vascular surgery
- Small reduction in CV outcome after ischemic stroke with lower LDL target, but also harms; no change in all-cause mortality
- Icosapent ethyl reduces risk of CV death in patients with CV disease, low LDL, and high triglycerides (REDUCE-IT)
- In very-high-risk patients with vascular disease, evolocumab slightly reduces nonfatal MI but not mortality (FOURIER)
- Adding coronary computed tomographic angiogram to chest pain assessment reduces likelihood of nonfatal myocardial infarction over 10 years (SCOT-HEART)
- Niacin not effective in CAD with low HDL cholesterol (AIM-HIGH)